Therapeutic options for infections caused by gram-negative organisms expressing plasmid-
mediated AmpC β-lactamases are limited because these organisms are usually resistant to …

Although plasmid-mediated AmpC β-lactamases were first reported in the late 1980s, many
infectious disease personnel remain unaware of their clinical importance. These enzymes …

AmpC beta-lactamases are cephalosporinases that confer resistance to a wide variety of β-
lactam drugs and that may thereby create serious therapeutic problems. Although reported …

Methods: A total of 241 nosocomial isolates of K. pneumoniae (n= 109) and E. coli (n= 132)
from six geographically distant hospitals in India were included. These were screened for …

Escherichia coli that produce plasmid-mediated AmpC β-lactamases are rare in the United
States. The clinical features associated with infection with these organisms have not been …

Two mechanisms account for AmpC activity in Escherichia coli, namely, mutations in the
ampC promoter and attenuator regions resulting in ampC overexpression and acquisition of …

The aim of this study was to investigate the prevalences of plasmid-mediated AmpC β-
lactamases (PABLs) in isolates of Escherichia coli and Klebsiella spp. from a university …

The aim of the study is to investigate the prevalence of plasmid-mediated AmpC β-
lactamases in Enterobacteriaceae naturally lacking chromosomal AmpC β-lactamases. A …

The dogma that ampC genes are located exclusively on the chromosome was dominant
until about 10 years ago. Since 1989 over 15 different plasmid-encoded AmpC β …

Non-beta-lactam inhibitor-based methods were evaluated for detecting plasmid-mediated
AmpC β-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. Using CLSI …